Want to see NEO full AI Analyst Report?
Top Page
NeoGenomics
(NASDAQ:NEO)
Select Model
Select Model
Rating:60Neutral
Price Target:
$19.50
▲(12.26% Upside)
Action:Reiterated
Date:08/17/26
NEO scores as a balanced opportunity: the biggest constraint is financial performance, where growth and improving cash generation are offset by continued net losses and slightly negative free cash flow. Technicals are supportive with strong upward trend and positive momentum. The latest earnings call reinforces improving fundamentals via raised revenue and EBITDA guidance and margin progress, while valuation remains constrained by negative earnings and the absence of a dividend yield.
Positive Factors
Clinical and NGS growth
Strong clinical growth reinforces NeoGenomics’ core oncology positioning, while rapid NGS expansion increases exposure to higher-complexity testing. Continued adoption of these services can support durable revenue growth and strengthen the company’s relevance to providers and precision-medicine programs over the coming quarters.
Negative Factors
Ongoing losses and negative free cash flow
NeoGenomics remains loss-making despite narrowing deficits and improving margins, while slightly negative free cash flow shows that operations are not yet fully funding investment needs. Persistent losses can constrain internal capital generation and make sustained execution more dependent on continued improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical and NGS growth
Strong clinical growth reinforces NeoGenomics’ core oncology positioning, while rapid NGS expansion increases exposure to higher-complexity testing. Continued adoption of these services can support durable revenue growth and strengthen the company’s relevance to providers and precision-medicine programs over the coming quarters.
Read all positive factors
NeoGenomics Key Performance Indicators (KPIs)
Any
Net Revenue by Customer Type
Shows how NeoGenomics' net revenue is split across customer groups—hospitals, reference labs, pharma/biotech and clinical-trial partners—revealing where growth is coming from, concentration risk or customer dependence, and sensitivity to pricing, reimbursement, or drug-development cycles.
Shows how NeoGenomics' net revenue is split across customer groups—hospitals, reference labs, pharma/biotech and clinical-trial partners—revealing where growth is coming from, concentration risk or customer dependence, and sensitivity to pricing, reimbursement, or drug-development cycles.
Data provided by:
The Fly
The FlyNeoGenomics (NEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.41B
Dividend Yield0.75%
Average Volume (3M)1.93M
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue Growth11.19%
EPS Growth50.58%
CountryUS
Employees2,500
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.98
Shares Outstanding128,475,430
10 Day Avg. Volume2,533,866
30 Day Avg. Volume1,933,301
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.33Price Target Upside5.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)0.18
Revenue Forecast (FY)$804.16M
NeoGenomics Business Overview & Revenue Model
Company Description
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinica...
How the Company Makes Money
NeoGenomics primarily makes money by performing laboratory testing and related diagnostic services and recognizing revenue when it delivers test results or completes contracted services. Key revenue streams include: (1) Clinical testing services: ...
NeoGenomics Earnings Call Summary
Earnings Call Date:Jul 28, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed solid commercial and margin momentum driven by strong NGS and clinical performance, operational efficiencies from the Lab of the Future program, and constructive guidance and capital structure actions. Headwinds were concentrated in the smaller nonclinical/pharma segment (notably a 26% decline in Pharma revenue) and timing-sensitive items (reimbursement for RaDaR ST, a DOJ settlement impact, and a tougher Q3 comp from exiting a high-volume low-value contract). Overall, the company demonstrated durable clinical growth, margin expansion and strengthened liquidity while acknowledging discrete near-term challenges that management plans to address.Positive Updates
Commercial Execution and Organizational Scaling
Reorganized commercial team into two ecosystems (oncology and pathology); on track to exceed 160 commercial reps in Q3; Net Promoter Score in the high 70s across pathology and oncology indicating strong customer experience.
Negative Updates
Nonclinical / Pharma Weakness
Nonclinical revenue was $14.5M, down 15% YoY; Pharma revenue declined 26% YoY (Pharma represents ~5% of total revenue) and the company lowered expectations for Pharma, expecting nonclinical down high-single-digits for 2026.
Read all updates
Q2-2026 Updates
Positive
Negative
Commercial Execution and Organizational Scaling
Reorganized commercial team into two ecosystems (oncology and pathology); on track to exceed 160 commercial reps in Q3; Net Promoter Score in the high 70s across pathology and oncology indicating strong customer experience.
Read all positive updates
Company Guidance
NeoGenomics raised full‑year 2026 revenue guidance to $802–$806 million (from $797–$803M) after a strong Q2 (revenue $201.7M, +11% YoY), driven by clinical growth (+14% YoY) with AUP +12% and volumes +2%; NGS revenue is now expected to grow in the mid‑20s (Q2 NGS +26%, representing ~1/3 of clinical revenue). Management left RaDaR ST and PanTracer LBx revenue assumptions unchanged (mid‑single‑digit millions), now expects the nonclinical segment to be down high‑single digits for 2026 (versus prior down low‑to‑mid‑single digits), and suggests modeling ~10% revenue growth in Q3 and above 10% in Q4. They forecast full‑year adjusted gross margin improvement of ~100–150 bps (Q2 adj. gross margin was 48.1%, +260 bps Y/Y) and raised adjusted EBITDA guidance to $56–$58M (from $55–$57M), implying >30% YoY growth at the midpoint and targeting low‑30s % adj. EBITDA growth in Q3 and Q4.NeoGenomics Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
58
Neutral
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 766.29M | 727.33M | 660.57M | 591.64M | 509.73M | 484.33M |
| Gross Profit | 328.90M | 282.54M | 290.10M | 244.60M | 187.90M | 187.06M |
| EBITDA | 12.89M | -38.69M | -1.51M | -17.61M | -82.33M | 46.50M |
| Net Income | -51.88M | -108.03M | -78.73M | -87.97M | -144.25M | -8.35M |
Balance Sheet | ||||||
| Total Assets | 1.35B | 1.36B | 1.64B | 1.68B | 1.74B | 1.87B |
| Cash, Cash Equivalents and Short-Term Investments | 145.54M | 159.62M | 386.84M | 415.20M | 437.99M | 515.39M |
| Total Debt | 448.37M | 472.28M | 605.33M | 611.68M | 610.93M | 612.79M |
| Total Liabilities | 565.65M | 523.27M | 735.70M | 739.69M | 742.01M | 761.50M |
| Stockholders Equity | 785.73M | 836.56M | 902.34M | 941.54M | 998.02M | 1.11B |
Cash Flow | ||||||
| Free Cash Flow | -7.36M | -21.78M | -34.04M | -30.70M | -96.88M | -90.86M |
| Operating Cash Flow | 22.05M | 5.23M | 7.02M | -1.95M | -65.99M | -26.72M |
| Investing Cash Flow | -19.90M | -12.34M | 12.86M | 76.71M | 517.00K | -632.37M |
| Financing Cash Flow | -11.39M | -200.29M | 4.65M | 4.55M | 11.83M | 725.28M |
NeoGenomics Technical Analysis
Neutral
17.37
Price Trends
17.04
Positive
14.35
Positive
12.26
Positive
Market Momentum
0.57
Positive
51.48
Neutral
29.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEO, the sentiment is Neutral. The current price of 17.37 is below the 20-day moving average (MA) of 18.52, above the 50-day MA of 17.04, and above the 200-day MA of 12.26, indicating a neutral trend. The MACD of 0.57 indicates Positive momentum. The RSI at 51.48 is Neutral, neither overbought nor oversold. The STOCH value of 29.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NEO.
NeoGenomics Risk Analysis
NeoGenomics disclosed 43 risk factors in its most recent earnings report. NeoGenomics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeoGenomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $25.60B | 24.43 | 14.49% | 1.42% | 9.87% | 12.51% | |
71 Outperform | $1.07B | -53.87 | -4.15% | ― | 3.18% | -100.37% | |
69 Neutral | $25.04B | 25.32 | 11.57% | 0.93% | 6.41% | 33.31% | |
69 Neutral | $3.70B | 31.97 | 8.64% | ― | 17.28% | 323.64% | |
60 Neutral | $2.41B | -9.25 | -6.31% | 0.75% | 11.19% | 50.58% | |
60 Neutral | $23.85B | -51.11 | 211.46% | ― | 42.74% | -4.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
NEO
NeoGenomics
18.36
9.38
104.45%
LH
Labcorp Holdings
308.11
31.47
11.38%
DGX
Quest Diagnostics
233.07
55.23
31.06%
VCYT
Veracyte
46.04
10.41
29.22%
GH
Guardant Health
178.36
116.90
190.21%
CSTL
Castle Biosciences
35.53
13.30
59.83%
NeoGenomics Corporate Events
Executive/Board Changes
NeoGenomics Announces Planned Transition of General Counsel Role
Neutral
Aug 11, 2026
NeoGenomics announced on August 11, 2026, that Alicia Olivo, its EVP, General Counsel Business Development, will step down as General Counsel effective September 21, 2026, and remain with the company until October 2, 2026 for transition purposes....
Business Operations and StrategyLegal Proceedings
NeoGenomics Resolves DOJ Investigation, Refocuses on Cancer Care
Positive
Jul 20, 2026
On June 20, 2026, NeoGenomics finalized a civil settlement with the U.S. Department of Justice, acting on behalf of the OIG-HHS, resolving a government investigation into consulting services provided to certain health care providers for laboratory...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.